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Effects of Conflict-of-Interest Policies in Psychiatry Residency on Antidepressant
Prescribing
Abstract
Concerns about the pharmaceutical industry’s influence in academic medical centers and on medical
education have led many medical schools and teaching hospitals to adopt conflict-of-interest (COI)
policies. Although the restrictiveness of these policies differs, the goal is the same: to shield physiciansin-training from the persuasive aspects of pharmaceutical promotion. But do these policies work? This
Issue Brief examines how COI policies affect the prescribing patterns of antidepressants, one of the most
heavily promoted drug classes in the past decade. As such, it provides the first empirical evidence of the
effects of COI policies in residency on the subsequent prescribing patterns of practicing physicians.
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Editor’s note: Concerns about the pharmaceutical industry’s influence in
academic medical centers and on medical education have led many medical
schools and teaching hospitals to adopt conflict-of-interest (COI) policies.
Although the restrictiveness of these policies differs, the goal is the same: to shield
physicians-in-training from the persuasive aspects of pharmaceutical promotion.
But do these policies work? This Issue Brief examines how COI policies affect the
prescribing patterns of antidepressants, one of the most heavily promoted drug
classes in the past decade. As such, it provides the first empirical evidence of the
effects of COI policies in residency on the subsequent prescribing patterns of
practicing physicians.
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Policies target
interactions between
physician trainees and
pharmaceutical companies

Physicians interact with the pharmaceutical industry throughout their professional
lives—from medical school through residency training, and commonly in clinical
practice. There is particular concern about industry influence on physician
trainees, who are beginning to establish long-term practice patterns. In the past
10 years, a number of guidelines have emerged to structure these interactions.
• In 2002, the Pharmaceutical Research and Manufacturers Association (PhRMA)
issued voluntary guidelines for sales representatives that limited the value of
gifts to physicians to under $100, along with other restrictions. At the same
time, the American Medical Student Association (AMSA) began a PharmFree
Campaign to limit the access and influence of pharmaceutical companies at
medical schools and academic medical centers.
• In 2008, the Association of American Medical Colleges (AAMC) developed
consensus principles for COI policies, including a prohibition on all gifts to
health care professionals. The AAMC guidelines addressed other interactions as
well, including meals, pharmaceutical samples, and site access by
sales representatives.
• Since 2007, AMSA has issued an annual “PharmFree Scorecard” grading each
medical school’s COI policy for its content and stringency. This scorecard shows
that academic medical centers vary widely in their adoption of COI policies,
even after the AAMC guidelines were issued. In 2011-12, 18% of US medical
schools received an “A,” 49% a “B,” 10% a “C,” 9% a “D”, and 6% an “F.”

New study looks at how
conflict of interest (COI)
policies are associated
with subsequent
prescribing patterns

Although many studies indicate that contact with the pharmaceutical industry
can affect physicians’ attitudes and prescribing choices, it is unknown whether
exposure to COI policies during residency training attenuates that influence after
graduation. Epstein and colleagues chose to study one specialty—psychiatry—
and one class of drug—antidepressants—to begin to answer that question.
Antidepressants have been among the most heavily promoted drug classes, and
antidepressant use increased nearly 400% from 1988 to 2008.
• The investigators used national prescribing data for 2009 and compared two
cohorts of psychiatrists: those completing residency in 2001 (before COI policy
adoption) and those completing residency in 2008 (after COI policy adoption).
• They used data from the 2008 AMSA PharmFree Scorecard and the Institute
for Medicine as a Profession (IMAP) to sort the 2008 COI policies of
residency programs into three levels of restrictiveness (maximally, moderately,
or minimally restrictive). The categorization was based on 10 aspects of each
program’s policy: gifts, on-site meals, detailing, samples, purchasing and
formularies, continuing medical education, consulting, speaking, travel, and
industry support for trainees.
• They analyzed the proportions of new prescriptions written by each psychiatrist
for antidepressants that were: (1) heavily promoted; (2) brand reformulated
(for example, controlled released versions); and (3) brand drugs. They
categorized Lexapro and Cymbalta as heavily promoted, because these
antidepressants were ranked first and third among all pharmaceuticals by
promotional spending in 2009.
• To estimate the effects of exposure to COI policies, the investigators compared
the average difference in prescribing during 2009 between psychiatrists
who graduated in 2001 and in 2008 from residency programs that adopted
maximally, moderately and minimally restrictive COI policies. If COI policies
“work” as intended, the prescription patterns of 2008 graduates of the most
restrictive programs should vary the most from their 2001 predecessors,
compared to the least restrictive programs.

Study analyzes more than
900,000 new prescriptions
for antidepressants by
psychiatrists

The study included 1,652 psychiatrists, about half of whom graduated in 2001
and half in 2008. They accounted for 901,805 new dispensed prescriptions for
antidepressants in 2009.
• The psychiatrists graduated from 162 residency programs. Categorized by
their program’s 2008 COI policy, about 30% graduated from the minimally
restrictive group, 51% from the moderately restrictive group, and 19% from the
maximally restrictive group.
• Overall, the 2008 graduates prescribed far fewer antidepressants than the
2001 graduates, likely because they were in their first year of practice and
consequently saw fewer patients.
• Not surprisingly, the rates of prescribing new dispensed antidepressants among
2001 graduates were not significantly different across residency program groups,
since the COI policies were not in place at that time.

Exposure to restrictive COI
policies in residency is
associated with changes in
prescribing patterns
in practice

Rates of prescribing heavily promoted, brand reformulated, and brand
antidepressants in 2009 were lower among post-COI graduates at all levels of COI
restrictiveness. But the largest differences between pre- and post-COI graduates
appeared in the maximally restrictive programs.
• As shown below, relative to the 2001 graduates in the same residency group,
2008 graduates in maximally restrictive programs prescribed heavily marketed
antidepressants significantly less often than 2008 graduates of both minimally
restrictive programs (4.3 percentage points) and moderately restrictive programs
(3.6 percentage points).

• Results were consistent for prescribing of brand reformulations and brand
drugs. Relative to the 2001 graduates in the same residency group (who
completed their training before their program adopted COI policies),
prescribing rates among 2008 graduates in maximally restrictive programs
were significantly lower than among 2008 graduates of minimally restrictive
programs for both reformulations (3.0 percentage points) and brand
antidepressants (4.5 percentage points).
• Results were similar when the analysis included both new and refilled
prescriptions for antidepressants.

POLICY IMPLICATIONS

Longstanding concerns have been raised about pharmaceutical industry influence
on physicians in general and trainees in particular. This study provides the first
empirical evidence about whether COI policies reduce this influence.
• In psychiatry, physicians who were exposed to maximally restrictive COI
policies during residency training had lower rates of prescribing heavily
marketed antidepressants. Although physician-industry interactions may serve
an important informational function, these results offer one piece of evidence
that these COI policies have helped inoculate physicians against the persuasive
aspects of pharmaceutical promotion.

Continued on back.

POLICY IMPLICATIONS
Continued

• Because heavily marketed drugs, reformulated drugs, and brand drugs tend
to be more expensive, a shift away from them could help reduce cost growth.
However, it will be important to assess how lower costs achieved through
stringent COI policies affect treatment effectiveness and quality of care.
• Further research should assess whether these policies have affected other drug
classes and physician specialties similarly.
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